Send me a link:

*Text messaging rates may apply.

 Dow Down0.87% Nasdaq Down0.73%

More On ONC.TO

Quotes

Charts

News & Info

Company

Analyst Coverage

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials


Oncolytics Biotech Inc. (ONC.TO)

-Toronto
1.53 Down 0.01(0.65%) 10:45AM EDT
ProfileGet Profile for:
Oncolytics Biotech Inc.
1167 Kensington Crescent NW
Suite 210
Calgary, AB T2N 1X7
Canada - Map
Phone: 403-670-7377
Fax: 403-283-0858
Website: http://www.oncolyticsbiotech.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:N/A

Business Summary 

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Oncolytics Biotech Inc.

Key Executives 
 PayExercised
Dr. Bradley G. Thompson Ph.D.,
Exec. Chairman, Chief Exec. Officer and Pres
810.00K0.00
Mr. Kirk J. Look CA,
Chief Financial Officer, Principal Accounting Officer and Chief Financial Officer of Oncolytics Biotech (U.S.) Inc.
411.00K0.00
Dr. Matthew C. Coffey Ph.D.,
Chief Operating Officer and Director
529.00K0.00
Dr. George M. Gill M.D.,
Chief Safety Officer and Sr. VP of Clinical & Regulatory Affairs
458.00K0.00
Dr. Alan J. Tuchman M.D., MBA, (FANN), 67
Chief Medical Officer and Sr. VP of Medical & Clinical Affairs
207.00K0.00
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in CAD.